Barclays analyst Luke Sergott raised the firm’s price target on Exact Sciences (EXAS) to $65 from $55 and keeps an Overweight rating on the shares as part of a Q3 preview for the life science tools and diagnostics group. The firm views the companies’ end markets as stable with improvements likely going forward. In addition, investment sentiment “feels bottomed” as share valuations have come down, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences added to Q4 2025 Tactical Ideas List at Wells Fargo
- Exact Sciences Receives Buy Rating from Bruce Jackson Amid Promising MCED Test Launch and Strong Financial Projections
- Craig-Hallum healthcare/pharma analysts hold analyst/industry conference call
- Exact Sciences management to meet with Craig-Hallum
- Exact Sciences price target raised to $85 from $65 at Craig-Hallum